MiNK Therapeutics (NASDAQ:INKT) Shares to Reverse Split on Tuesday, January 28th

Shares of MiNK Therapeutics, Inc. (NASDAQ:INKT) are set to reverse split on the morning of Tuesday, January 28th. The 1-10 reverse split was announced on Tuesday, January 21st. The number of shares owned by shareholders will be adjusted after the market closes on Monday, January 27th.

MiNK Therapeutics Price Performance

Shares of NASDAQ:INKT opened at $0.98 on Friday. The business’s 50-day moving average is $0.71 and its 200 day moving average is $0.77. MiNK Therapeutics has a 1 year low of $0.46 and a 1 year high of $1.90. The firm has a market capitalization of $38.64 million, a P/E ratio of -2.50 and a beta of 0.10.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on INKT shares. Robert W. Baird reduced their target price on MiNK Therapeutics from $8.00 to $4.00 and set an “outperform” rating on the stock in a research report on Friday, November 15th. HC Wainwright reaffirmed a “buy” rating and set a $9.00 target price on shares of MiNK Therapeutics in a research report on Friday, November 15th.

Institutional Inflows and Outflows

An institutional investor recently raised its position in MiNK Therapeutics stock. Renaissance Technologies LLC grew its position in MiNK Therapeutics, Inc. (NASDAQ:INKT) by 21.5% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 127,841 shares of the company’s stock after purchasing an additional 22,613 shares during the period. Renaissance Technologies LLC owned approximately 0.37% of MiNK Therapeutics worth $121,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 2.87% of the company’s stock.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.